Immunogenicity of Heterologous SARS-CoV-2 PHH-1V Protein Booster vaccination in People with Immunocompromising Conditions

For people whose immune systems are weakened by illness or medication, the fight against viruses is often an uphill battle. Their bodies struggle to build the defenses needed to stop infections, making standard vaccines less effective and leaving them vulnerable to severe disease. When the SARS-CoV-2 virus emerged, scientists knew that a single shot of a vaccine might not be enough for these individuals. They needed a way to wake up the immune system again, to remind it of the threat and train it to fight back. This is where the concept of a "booster" comes in: an extra dose given after the initial series to strengthen and extend protection. However, not all boosters work the same way for everyone. While some rely on genetic instructions to teach cells how to make a viral protein, others use the actual protein itself, mixed with a substance that helps the body recognize it. Understanding which approach works best for the most vulnerable people is critical, as their immune systems may react differently to these various methods.

A team of researchers set out to test one such protein-based booster in a large group of adults with different types of immune problems. The study, known as HIPRA-HH-4, focused on five distinct groups: people living with HIV who had low levels of immune cells, kidney transplant recipients taking drugs to prevent organ rejection, patients on dialysis for kidney failure, individuals with a rare condition where their bodies cannot make enough antibodies, and those with autoimmune diseases treated with drugs that wipe out specific immune cells. All of these participants had already received their primary series of mRNA vaccines, the type that became widely known during the early pandemic. The researchers wanted to see if adding this new protein booster would help their bodies produce better defenses against the virus, specifically against the Omicron variants that were circulating at the time. They also wanted to track how long these defenses lasted and whether the vaccine was safe for these fragile populations.

The results showed that for most of the groups, the booster worked well. Within two weeks of receiving the shot, the participants' bodies began producing significantly higher levels of antibodies, the proteins that can neutralize the virus. This was true for people with HIV, kidney transplant recipients, and those on dialysis. Their immune systems responded by making antibodies that could recognize and fight off several versions of the Omicron virus, including the specific subtypes that were dominant when the study began. The protection was not just limited to the exact strain used in the vaccine; the antibodies also showed a ability to cross-react with the original SARS virus from 2003, suggesting a broadening of the immune memory. However, the story was different for the two groups whose immune systems were most severely suppressed by their treatments. People with primary antibody deficiency and those with autoimmune diseases treated with drugs that deplete B-cells did not show a significant rise in antibodies. Their bodies simply could not manufacture the necessary proteins in response to the shot, highlighting a hard limit on what a vaccine can achieve when the factory itself is missing.

Beyond the antibodies, the researchers looked at the cellular side of the immune response, specifically the T-cells, which act as the body's internal security force. Even in the groups that failed to produce antibodies, the vaccine managed to boost these T-cell defenses. This is a crucial finding because it suggests that the vaccine might still offer some protection against severe disease, even if it cannot prevent infection entirely. The T-cells were particularly active in people with HIV and those on dialysis, showing that their immune systems retained the ability to learn and adapt. The study also tracked how long these protections lasted. By one year, the levels of antibodies had dropped significantly in all groups, returning to near-baseline levels. This indicates that while the booster provided a strong, immediate surge of protection, it did not create a permanent shield. The immune response faded over time, suggesting that these vulnerable individuals might need more frequent boosters to stay protected, perhaps every six months rather than once a year.

Safety was another major focus of the study. The researchers monitored participants closely for any negative reactions, from pain at the injection site to more serious systemic issues. The vaccine proved to be well-tolerated across all groups. Most side effects were mild or moderate, such as soreness in the arm or temporary fatigue, and they resolved quickly. Serious adverse events were rare and, importantly, none were linked to the vaccine itself. The few severe reactions that did occur, such as infections or heart issues, were attributed to the participants' underlying health conditions rather than the shot. This safety profile is vital, as it means that doctors can offer this booster to high-risk patients without fear of causing harm, even when their immune systems are already compromised.

The study also examined real-world outcomes by tracking how many participants caught the virus after vaccination. Over the course of the year, a number of people did experience breakthrough infections, but the vast majority were mild. Only a handful of participants required hospitalization, and there were no deaths linked to the virus within the study group. This suggests that even when the vaccine did not prevent infection entirely, it likely helped keep the disease from becoming severe. The data also revealed that people who had been infected with the virus before the study started tended to have stronger immune responses afterward, regardless of their underlying condition. This "hybrid immunity," combining past infection with vaccination, appeared to provide a more robust defense than vaccination alone.

Ultimately, this research provides a clear map of how different types of immunocompromised people respond to a protein-based booster. It confirms that for many, including those with HIV and kidney disease, the vaccine is a powerful tool that can significantly raise their defenses. For others, particularly those with B-cell depletion, the vaccine alone is not enough to generate antibodies, pointing to the need for other strategies like passive immunity or different types of treatments. The study underscores that there is no one-size-fits-all solution for immune protection. Instead, the path forward requires tailored approaches that recognize the specific limitations of each patient's immune system. By understanding exactly how these groups react, doctors can make better decisions about when and how to vaccinate, ensuring that the most vulnerable among us are given the best possible chance to stay safe.